Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

51results about How to "Diminishment of extent" patented technology

Recombinant adenoviruses and use thereof

The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
Owner:WASHINGTON UNIV IN SAINT LOUIS +1

Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

InactiveUS20170020877A1Reduce high plasma ACTH levelPotent capability for lowering ACTHOrganic active ingredientsEndocrine system disorderSide effectPhysiology
CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Owner:NEUROCRINE BIOSCI INC

Indole compounds and methods for treating visceral pain

The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D / 1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The methods of the invention may further comprise the administration of additional therapeutic agent. The invention also features new compounds of Formula (I), pharmaceutical compositions thereof, and methods of resolving enantiomeric mixtures.
Owner:NEURAXON INC

Method of enhancing hair growth

Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include bimatoprost and minoxidil in a vehicle for topical application to the skin of a mammal, e.g. a human, whereby the combination of bimatoprost and minoxidil produces a faster onset of hair growth in humans or other mammals and wherein said composition brings about a synergestic result of faster onset of hair growth as compared to compositions comprising bimatoprost and minoxidil, alone.
Owner:ALLERGAN INC

Methods for treating diseases related to the wnt pathway

The present invention relates to methods for treating a disease, in which the disease arises from dysregulation of the Wnt signaling pathway. In some instances, the disease can be treated by administering a Wnt pathway inhibitory compound. In other instances, the method optionally includes conducting a genome-wide screening to determine one or more genes resulting in a reduced disease state and then identifying the gene(s) as being involved in the Wnt signaling pathway.
Owner:NAT TECH & ENG SOLUTIONS OF SANDIA LLC

Methods for the treatment of cysteamine sensitive disorders

The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.
Owner:THIOGENESIS THERAPEUTICS INC

Treatments for mycobacterium tuberculosis

InactiveUS20140243255A1Diminishment of extentAmelioration and palliation of disorderAntibacterial agentsOrganic active ingredientsProteaseMycobacterium
The technology described herein relates to treatments for tuberculosis which target the ClpP1P2 protease complex, including ClpC1. Further embodiments relate to assays and screens for modulators of the ClpP1P2 protease complex, including ClpC1.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Methods, systems, and compositions for maintaining functioning drainage blebs associated with minimally invasive micro sclerostomy

ActiveUS20200101318A1Reducing and inhibiting treatment-induced scar formationGuaranteed functionMedical devicesIntravenous devicesIntra ocular pressureSclerostomy
Methods, systems, and compositions for maintaining functioning drainage blebs to reduce intraocular pressure (IOP) of an eye being treated for glaucoma. The methods, systems, and compositions feature the combination of a minimally invasive micro sclerostomy (MIMS) procedure and the application of beta radiation to a target area. The beta radiation can function to inhibit or reduce the inflammation and / or fibrogenesis that typically occurs after a MIMS procedure and leads to hole and / or bleb failure. By reducing inflammation and / or fibrogenesis, the MIMS holes and / or blebs can remain functioning appropriately.
Owner:RADIANCE THERAPEUTICS INC

Tunable metal-organic framework compositions and methods thereof

The present invention relates to a metal-organic framework composition, as well as constructs and methods thereof. In one particular example, the composition provides a platform having an emission signal in the deep red to near-infrared (NIR) region.
Owner:NAT TECH & ENG SOLUTIONS OF SANDIA LLC

Degradation of chemical agents using metal-organic framework compositions

The present invention relates to a metal-organic framework composition, as well as constructs and methods thereof. In one particular example, the composition is employed to degrade a chemical agent in a non-aqueous environment.
Owner:NAT TECH & ENG SOLUTIONS OF SANDIA LLC

Polymorphs of sepiapterin and salts thereof

Disclosed are crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F, and G, and combinations thereof, as well as crystalline polymorphs of salts of sepiapterin. Also disclosed are pharmaceutical compositions containing one or more such polymorphs and methods for preparing such polymorphs. Sepiapterin is useful in the treatment of a number diseases associated with low cellular levels of BH4, for example, phenylketonuria.
Owner:PTC THERAPEUTICS MP INC

Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy

The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC

Polymorphic form of sepiapterin

ActiveUS20200010469A1Beneficial and desired clinical resultDiminishment of extentNervous disorderMetabolism disorderDiseaseIntracellular
Disclosed is a crystalline form of sepiapterin, a method of preparing the crystalline form, pharmaceutical compositions containing the crystalline form, and a method for treating patients with a disease associated with low intracellular BII4 levels or with dysfunction of various BII4 dependent metabolic pathways, which involves administering to the patient an effective amount of the crystalline form.
Owner:PTC THERAPEUTICS MP INC

Polymorphs of sepiapterin and salts thereof

Disclosed are crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F, and G, and combinations thereof, as well as crystalline polymorphs of salts of sepiapterin. Also disclosed are pharmaceutical compositions containing one or more such polymorphs and methods for preparing such polymorphs. Sepiapterin is useful in the treatment of a number diseases associated with low cellular levels of BH4, for example, phenylketonuria.
Owner:PTC THERAPEUTICS MP INC

Devices, kits, and methods for determining ineffectiveness of anesthetics

In general, the invention provides kits, devices, and methods for determining the ineffectiveness of an anesthetic, (e.g., lidocaine), using a topical approach that avoids injection. The methods typically employ the placement of aliquots of two different formulations, at least one including an anesthetic, in different locations on a subject. Further embodiments may employ a single formulation including the anesthetic.
Owner:ALKALIDX INC

Site-specific labeling and targeted delivery of proteins for the treatment of cancer

The present invention relates to the formation of protein conjugates from proteins chemically modified for linkage to (1) anticancer drug pharmacophores, (2) ligands to biomarkers on cancer cell surfaces, (3) and / or another protein molecule. It provides and specifies new compositions, methods and combinations for tumor, and tumor vasculature targeting and cancer treatment.
Owner:ADVANCED PROTEOME THERAPEUTICS

Method of enhancing hair growth

Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include bimatoprost and minoxidil in a vehicle for topical application to the skin of a mammal, e.g. a human, whereby the combination of bimatoprost and minoxidil produces a faster onset of hair growth in humans or other mammals and wherein said composition brings about a synergestic result of faster onset of hair growth as compared to compositions comprising bimatoprost and minoxidil, alone.
Owner:ALLERGAN INC

Novel Protein With Anti-Inflammatory Properties

The present invention provides an isolated or recombinant protein consisting of the amino acid sequence according to SEQ ID NO: 3 or SEQ ID: NO: 4 and its use in the prevention or treatment of an inflammatory condition.
Owner:REVOLO BIOTHERAPEUTICS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products